01.16.23 -- 4 Insights On CDMO Relationships From A Vaccine Developer

The $118 billion combination product market is projected to increase at a compound annual growth rate (CAGR) of 8.8%. This article answers the questions: “Is this actually a combination product? What do we need to do if it is?”

Singota combines small-batch capability and expertise, empowering clients through great flexibility and guidance through the manufacturing, documentation, QA, and regulatory process.

Successful tech transfer is how long-term strategic CDMO relationships begin. A product’s continued success may hinge on this critical exchange of product data and required regulatory filings.

Learn about a premier system offering a flexible LC platform that can be broadly deployed across labs to support analytical needs in the development and manufacture of biotherapeutics.

From sensors and software to data-based services throughout production, Industry 4.0 solutions are opening new potential in terms of transparency, quality, safety, and efficiency.

An established cell line and a bench-scale manufacturing process for a complex glycoprotein produced high-quality material but had a low yield and was not scalable.

Explore the needs of more complex candidates through case studies that demonstrate the range of expression capabilities across mammalian- and microbial-derived molecules.

Small, midsize, and large biotech companies discuss major hurdles they encountered and how a customer-centric CDMO partnership can help overcome these, dismissing the idea of one-size-fits-all.